Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15539793 | 1.00 | GLP1R (0.58) | GLP1RNOD1FOLH1GLO1EPHX2 | |
| SCHEMBL4968384 | 1.00 | GLP1R (0.58) | GLP1RNOD1FOLH1GLO1EPHX2 | |
| SCHEMBL29059949 | 0.98 | GLP1R (0.55) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL4535900 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL4004880 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL2181197 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL4543138 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL4561886 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL4541595 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL4558792 | 0.96 | GLP1R (0.63) | GLP1RNOD1FOLH1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-9708383-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-20130288960-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| EP-2637698-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130288960-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, VIP, IAPP | GLP1R 1/4885NOD1 362/4885FOLH1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.